MUMBAI, India, Oct. 27, 2026 /PRNewswire/ -- Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the Second Quarter (Q2) and Half Year (H1) ended 30(th) September 2026.
Consolidated Financial Highlights ------------------------------------------------------------------------------ (in Crores or as stated) ------------------------------------------------------------------------------ Particulars Q2FY27 Q2FY26 YoY Growth H1FY27 H1FY26 YoY Growth ---------------------- ------ ------ ---------- ------ ------ ---------- Revenue from Operations 2,617 2,044 28 % 4,887 3,977 23 % ---------------------- ------ ------ ---------- ------ ------ ---------- CDMO 1,424 1,044 36 % 2,611 2,041 28 % ---------------------- ------ ------ ---------- ------ ------ ---------- CHG 849 644 32 % 1,592 1,281 24 % ---------------------- ------ ------ ---------- ------ ------ ---------- PCH 359 319 13 % 706 621 14 % ---------------------- ------ ------ ---------- ------ ------ ---------- EBITDA 385 224 72 % 669 389 72 % ---------------------- ------ ------ ---------- ------ ------ ---------- EBITDA Margin 14.7 % 11.0 % 13.7 % 9.8 % ---------------------- ------ ------ ---------- ------ ------ ---------- PAT 5 (99) 105 % (64) (181) 64 % ---------------------- ------ ------ ---------- ------ ------ ----------
Key Highlights
-- Broad-based Revenue Growth: Revenue grew 28% YoY in Q2FY27 and 23% YoY in
H1FY27, driven by strong performance across all three businesses.
-- Significant Profitability Improvement: EBITDA increased 72% YoY in Q2FY27
and H1FY27, with over 350bps EBITDA margin expansion in both periods.
This was driven by higher capacity utilization, operating leverage,
disciplined execution, and sustained cost optimization initiatives.
-- Robust RFP Activity and Order Inflows: Added 22 new customers and
successfully hosted 110 customer audits in H1FY27.
-- Best-in-Class Quality & Compliance: Successfully completed 12 regulatory
inspections and 110 customer audits during H1FY27, while maintaining the
Company's track record of no Official Action Indicated classifications
across US FDA inspections.
-- Upgrade FY27 Outlook: Based on the strong first-half performance and
continued business momentum, we upgrade our FY27 outlook and now expect
revenue growth of 19% to 20%, accompanied by meaningfully higher
profitability.
Nandini Piramal, Chairperson, Piramal Pharma Limited said, "We delivered a strong H1FY27, with revenue growth of 23% and EBITDA margin expansion of over 350 basis points, driven by healthy demand across our businesses, disciplined execution, and improved operating leverage. The performance was led by our CDMO business, which grew 28% on the back of strong order inflows and robust execution. Our CHG business complemented this momentum with 24% growth, supported by inhalation anesthesia sales in ex-US markets and the integration of the Kenalog, while Consumer Healthcare continued to deliver steady 14% growth through the strong performance of Power Brands and e-commerce.
With H2 typically stronger than H1, we are well positioned to deliver a strong full-year performance, supported by a healthy order book, encouraging customer engagement, and continued operating discipline."
Key Business Highlights ----------------------- Contract Development and Manufacturing Organization $(CDMO)$: Robust Growth: Broad-based growth across India and overseas sites, supported by healthy commercial demand, improved execution and disciplined cost management. India and North America led performance across the network. Enhanced Profitability: Better capacity utilization and operating leverage drove a meaningful improvement in profitability. Strong Commercial Momentum: Strong RFP activity and order inflows resulted in addition of 22 new customers during H1FY27. Phase III pipeline increased to 28 molecules from 25 as of March 2026. Innovation and On-Patent Revenue Growth: Innovation-related revenues grew 24%, while on-patent commercial manufacturing revenues grew 39% in H1FY27. Differentiated Capabilities: Strengthened biologics capabilities through acquisition of a controlling stake in Yapan Bio. The Lexington expansion remains on track, will add sterile fill-finish capabilities, completing the integrated ADC offering. Commissioned a new microbiology laboratory at the site. ADC Services continued to gain momentum, with revenues up 51% YoY in H1FY27. Deepening Customer Engagement: Successfully hosted 110 customer audits during H1FY27, reflecting continued customer engagement and confidence in the Company's quality systems. Complex Hospital Generics (CHG): Inhalation Anesthesia Leadership: Maintained leadership in the US Sevoflurane market with a 48% value share, while building traction in ex-US markets. (Source: IQVIA) Kenalog(R) Integration: Kenalog(R) contributed to CHG revenue during Q2FY27 and is expected to be an important growth driver for the business in FY27. Intrathecal Therapy: Maintained the #1 position in the US Intrathecal Baclofen market. (Source: IQVIA) Injectable Pain Management: Continued collaboration with suppliers to ensure product availability. Building a Differentiated and Specialty Portfolio: Continued investments in 505(b)(2) products, complex and differentiated generics, branded products, in-licensing and co-development to strengthen the long-term portfolio. Piramal Consumer Healthcare $(PCH)$: Power Brands Continue to Outperform: Power Brands grew 21% YoY in H1FY27, contributing 53% of PCH sales, reflecting the strength of the core portfolio. Strong E-commerce Momentum: Grew 32% YoY in H1FY27 and contributed 28% of PCH sales. Innovation and Premiumization: Continued focus on fewer, larger, and higher-potential launches to enhance portfolio quality and margins. Launched the 'Vizible' range under Lacto Calamine to strengthen presence in premium skincare. Sustained Brand Investments: Invested approximately 11% of PCH sales in media and trade promotion across digital and traditional channels to support long-term brand growth. Bayer Distribution Agreement: The distribution agreement will naturally expire in December 2026. The transition is being jointly managed to ensure business continuity, with no material impact expected on FY27 guidance. ------------------------------------------------------------------------------ Consolidated Profit and Loss Statement ------------------------------------------------------------------------------------------ (in Crores or as stated) ------------------------------------------------------------------------------------------ Quarterly Half Yearly -------------- ---------------------------------------------- -------------------------- Particulars Q2FY27 Q2FY26 YoY Change Q1FY26 QoQ Change H1FY27 H1FY26 YoY Change -------------- ------ ------ ---------- ------ ---------- ------ ------ ---------- Revenue from Operations 2,617 2,044 28 % 2,270 15 % 4,887 3,977 23 % -------------- ------ ------ ---------- ------ ---------- ------ ------ ---------- Other Income 36 66 -45 % 89 (60) % 125 124 1 % -------------- ------ ------ ---------- ------ ---------- ------ ------ ---------- Total Income 2,653 2,109 26 % 2,359 12 % 5,012 4,101 22 % -------------- ------ ------ ---------- ------ ---------- ------ ------ ---------- Material Cost 906 703 29 % 852 6 % 1,758 1,397 26 % -------------- ------ ------ ---------- ------ ---------- ------ ------ ---------- Employee Expenses 714 611 17 % 676 6 % 1,390 1,230 13 % -------------- ------ ------ ---------- ------ ---------- ------ ------ ---------- Other Expenses 648 571 13 % 547 18 % 1,195 1,085 10 % -------------- ------ ------ ---------- ------ ---------- ------ ------ ---------- EBITDA 385 224 72 % 285 35 % 669 389 72 % -------------- ------ ------ ---------- ------ ---------- ------ ------ ---------- Interest Expenses 88 82 6 % 88 (1) % 176 169 4 % -------------- ------ ------ ---------- ------ ---------- ------ ------ ---------- Depreciation 233 203 15 % 224 4 % 457 400 14 % -------------- ------ ------ ---------- ------ ---------- ------ ------ ---------- Share of Net Profit of Associates 18 15 20 % 20 (9) % 37 33 12 % -------------- ------ ------ ---------- ------ ---------- ------ ------ ---------- Profit Before Tax 82 (46) 277 % (7) 1,194 % 74 (146) 151 % -------------- ------ ------ ---------- ------ ---------- ------ ------ ---------- Tax 77 53 44 % 62 24 % 139 56 149 % -------------- ------ ------ ---------- ------ ---------- ------ ------ ---------- Net Profit after Tax 5 (99) 105 % (69) 107 % (64) (202) 68 % -------------- ------ ------ ---------- ------ ---------- ------ ------ ---------- Exceptional
item1 - - NA - NA - 21 NA
-------------- ------ ------ ---------- ------ ---------- ------ ------ ----------
Net Profit
after Tax
after
Exceptional
Item 5 (99) 105 % (69) 107 % (64) (181) 64 %
-------------- ------ ------ ---------- ------ ---------- ------ ------ ----------
1. Exceptional items include, one time insolvency proceeds received from a
claim filed against a third-party supplier of our complex hospital
generics business, with the NCLT in November 2023
Consolidated Balance Sheet
----------------------------------------
(in Cr. or as stated)
--------------------------------------------------------------
As at
---------------------------------------- --------------------
Key Balance Sheet Items 30-Sep-26 31-Mar-26
---------------------------------------- --------- ---------
Total Equity 8,165 8,162
---------------------------------------- --------- ---------
Net Debt 4,859 4,164
---------------------------------------- --------- ---------
Total 13,023 12,326
---------------------------------------- --------- ---------
Net Fixed Assets 10,448 9,784
---------------------------------------- --------- ---------
Tangible Assets 4,923 4,843
---------------------------------------- --------- ---------
Intangible Assets including goodwill 4,254 3,841
---------------------------------------- --------- ---------
CWIP (including IAUD2) 1,271 1,100
---------------------------------------- --------- ---------
Net Working Capital 2,260 2,081
---------------------------------------- --------- ---------
Other Assets3 315 462
---------------------------------------- --------- ---------
Total Assets 13,023 12,326
---------------------------------------- --------- ---------
Earnings Conference Call
Piramal Pharma Limited will be hosting a conference call for investors / analysts on 28(th) October 2026 from 10:00 AM to 10:45 AM (IST) to discuss its Q2 and H1 FY2027 Results.
The dial-in details for the call are as under:
Event Location & Time Telephone Number
------------------------- ------------------------- ------------------------
+91 22 6280 1461 / +91
22 7115 8320 (Primary
Number)
------------------------- ------------------------- ------------------------
India -- 10:00 AM IST 1 800 120 1221 (Toll
free number)
------------------------- ------------------------
USA -- 12:30 AM (Eastern Toll free number
Time -- New York) 18667462133
------------------------- ------------------------
UK -- 04:30 AM Toll free number
(London Time) 08081011573
------------------------- ------------------------
Singapore -- 12:30 PM Toll free number
(Singapore Time) 8001012045
------------------------- ------------------------
Conference call on Hong Kong -- 12:30 PM Toll free number
28(th) October 2026 (Hong Kong Time) 800964448
------------------------- ------------------------- ------------------------
Express Join with Diamond Please use this link for prior registration to
Pass(TM) reduce wait time at the time of joining the call
--Click here
------------------------- ---------------------------------------------------
About Piramal Pharma Limited:
Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the Piramal Consumer Healthcare (PCH) business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market.
For more information, visit: Piramal Pharma | LinkedIn
View original content to download multimedia:https://www.prnewswire.com/news-releases/piramal-pharma-limited-announces-results-for-q2-and-h1-fy27-302921172.html
SOURCE Piramal Pharma Limited
Comments